Identification

Name
Prasterone
Accession Number
DB01708  (EXPT00519, DB06593)
Type
Small Molecule
Groups
Approved, Nutraceutical
Description

Prasterone, also known as dehydroepiandrosterone (DHEA) is a major C19 steroid produced by the adrenal cortex. It is also produced in small quantities in the testis and the ovary. Dehydroepiandrosterone (DHEA) can be converted to testosterone; androstenedione; estradiol; and estrone. Most of DHEA is sulfated (dehydroepiandrosterone sulfate) before secretion.

In the United States, DHEA or DHEAS have been advertised with claims that they may be beneficial for a wide variety of ailments. DHEA and DHEAS are readily available in the United States, where they are marketed as over-the-counter dietary supplements. In November 2016, DHEA was approved (as Intrarosa) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.

In Canada, a prescription is required to buy DHEA.

Structure
Thumb
Synonyms
  • 3-beta-hydroxy-5-androsten-17-one
  • 3beta-hydroxyandrost-5-en-17-one
  • 3β-hydroxyandrost-5-en-17-one
  • Dehydroandrosterone
  • Dehydroepiandrosterone
  • Dehydroisoandrosterone
  • DHEA
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
IntrarosaInsert6.5 mg/1VaginalAmag Pharmaceuticals Inc2017-06-06Not applicableUs
International/Other Brands
Biolaif / Fidelin (Paladin) / OVIGYN-D (Alembic Pharmaceuicals Ltd)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
PrasteraPrasterone + IbuprofenKitOralHealth Science Funding, Llc2014-04-04Not applicableUs
Categories
UNII
459AG36T1B
CAS number
53-43-0
Weight
Average: 288.4244
Monoisotopic: 288.20893014
Chemical Formula
C19H28O2
InChI Key
FMGSKLZLMKYGDP-USOAJAOKSA-N
InChI
InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3/t13-,14-,15-,16-,18-,19-/m0/s1
IUPAC Name
(1S,2R,5S,10R,11S,15S)-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-7-en-14-one
SMILES

Pharmacology

Indication

DHEA is taken as a supplement for a variety of unsubstantiated indications. The following indications have shown promise and are backed up by some scientific evidence: schizophrenia (DHEA may be more effective in women than men); improving the appearance of older people’s skin (taking DHEA by mouth seems to increase skin thickness and moisture, and decrease facial “age spots” in elderly men and women); improving ability to achieve an erection in men with sexual dysfunction. Additionally, DHEA has shown promise in improving symptoms of lupus (SLE). Taking DHEA by mouth along with conventional treatment may help reduce the number of times symptoms flare up and may allow a reduction in the dose of prescription drugs needed. DHEA may also help SLE symptoms such as muscle ache and mouth ulcers. DHEA also seems to strengthen bones in SLE patients being treated with high-dose steroids (corticosteroids). DHEA also shows promise in the treatment of osteoporosis. Taking DHEA by mouth daily seems to improve bone mineral density (BMD) in older women and men with osteoporosis or osteopenia (pre-osteoporosis). DHEA may also increase BMD in young women with the eating disorder called anorexia nervosa. DHEA is often prescribed in India for the induction of ovulation to improve chances of pregnancy.

Structured Indications
Not Available
Pharmacodynamics

DHEA is naturally produced from cholesterol through two cytochrome P450 enzymes. Cholesterol is converted to pregnenolone by the enzyme P450 scc (side chain cleavage); then another enzyme, CYP17A1, converts pregnenolone to 17α-Hydroxypregnenolone and then to DHEA. Regular exercise is known to increase DHEA production in the body. Calorie restriction has also been shown to increase DHEA in primates. Some theorize that the increase in endogenous DHEA brought about by calorie restriction is partially responsible for the longer life expectancy known to be associated with calorie restriction.

Mechanism of action

DHEA can be understood as a prohormone for the sex steroids. DHEAS may be viewed as buffer and reservoir. As most DHEA is produced by the zona reticularis of the adrenal cortex, it is argued that there is a role in the immune and stress response. As almost all DHEA is derived from the adrenal glands, blood measurements of DHEAS/DHEA are useful to detect excess adrenal activity as seen in adrenal cancer or hyperplasia, including certain forms of congenital adrenal hyperplasia. Women with polycystic ovary syndrome tend to have elevated levels of DHEAS.

TargetActionsOrganism
UEstrogen receptor alpha
binder
Human
UEstrogen receptor beta
activator
Human
UGABA-A receptor (anion channel)
antagonist
Human
UNMDA receptor
agonist
Human
UAndrogen receptor
agonist
Human
UEstradiol 17-beta-dehydrogenase 1Not AvailableHuman
UBile salt sulfotransferaseNot AvailableHuman
USulfotransferase family cytosolic 2B member 1Not AvailableHuman
UPeroxisome proliferator-activated receptor alpha
activator
Human
USigma non-opioid intracellular receptor 1
agonist
Human
UNuclear receptor subfamily 1 group I member 2
activator
Human
UNuclear receptor subfamily 1 group I member 3
activator
Human
USteroid Delta-isomeraseNot AvailablePseudomonas putida
UCholesterol oxidaseNot AvailableBrevibacterium sterolicum
Absorption

Following a 50-mg DHEA PO dose in cynomolgus monkeys, systemic availability was only 3.1 +/- 0.4%. [PMID: 12970301]

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic. As shown by their high conversion ratios (in a study involving cynomolgus monkeys), the major circulating metabolites of DHEA are DHEA-S, androsterone glucuronide, and androstane-3 alpha,17 beta-diol-glucuronide. [PMID: 12970301]

Route of elimination
Not Available
Half life

12 hours

Clearance
Not Available
Toxicity

Acute oral toxicity (LD50): >10000 mg/kg [Rat]. Lowest Published Toxic Dose (TDL) [Man] - Route: Oral; Dose: 10 mg/kg/2W intermittent.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Prasterone is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Prasterone.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Prasterone.Approved, Experimental, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Prasterone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Prasterone.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Prasterone.Approved, Withdrawn
AldesleukinPrasterone may decrease the antineoplastic activities of Aldesleukin.Approved
AlmasilateThe bioavailability of Prasterone can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Prasterone.Experimental
AloglutamolThe bioavailability of Prasterone can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Prasterone.Experimental
AluminiumThe bioavailability of Prasterone can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Prasterone can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Prasterone can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Prasterone can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Prasterone is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Prasterone.Approved
AmiodaroneThe metabolism of Prasterone can be decreased when combined with Amiodarone.Approved, Investigational
Amphotericin BPrasterone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Prasterone.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Prasterone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Prasterone.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Prasterone.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Prasterone.Approved, Investigational
AprepitantThe serum concentration of Prasterone can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe metabolism of Prasterone can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Prasterone can be decreased when combined with Atomoxetine.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Prasterone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Prasterone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Prasterone.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Prasterone.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when Prasterone is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Prasterone.Experimental
BendroflumethiazidePrasterone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Prasterone.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Prasterone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Prasterone.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Prasterone.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Prasterone.Experimental
Bismuth SubcitrateThe bioavailability of Prasterone can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Prasterone can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe metabolism of Prasterone can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Prasterone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Prasterone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Prasterone.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Prasterone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Prasterone.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Prasterone.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Prasterone.Experimental
BumetanidePrasterone may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Prasterone.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Prasterone can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Prasterone can be decreased when combined with Calcium silicate.Experimental
Capromab pendetidePrasterone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe metabolism of Prasterone can be increased when combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Prasterone.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Prasterone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Prasterone.Approved, Investigational
CeritinibThe serum concentration of Prasterone can be increased when it is combined with Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Prasterone.Approved, Vet Approved
ChlorothiazidePrasterone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe risk or severity of adverse effects can be increased when Prasterone is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorthalidonePrasterone may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Prasterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Prasterone.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Prasterone is combined with Cinoxacin.Approved, Investigational, Withdrawn
ClarithromycinThe metabolism of Prasterone can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Prasterone can be decreased when combined with Clemastine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Prasterone.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Prasterone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ClotrimazoleThe metabolism of Prasterone can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Prasterone can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Prasterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Prasterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Prasterone can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe risk or severity of adverse effects can be increased when Prasterone is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Prasterone.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Prasterone is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Prasterone is combined with Coumaphos.Vet Approved
CrizotinibThe metabolism of Prasterone can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Prasterone.Investigational
CyclopenthiazidePrasterone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Prasterone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Prasterone.Investigational
DabrafenibThe serum concentration of Prasterone can be decreased when it is combined with Dabrafenib.Approved
DaidzeinThe risk or severity of adverse effects can be increased when Prasterone is combined with Daidzein.Experimental
DanazolPrasterone may increase the fluid retaining activities of Danazol.Approved
DarunavirThe metabolism of Prasterone can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Prasterone can be increased when it is combined with Dasatinib.Approved, Investigational
DecamethoniumThe risk or severity of adverse effects can be increased when Prasterone is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Prasterone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Prasterone can be decreased when combined with Delavirdine.Approved
DemecariumThe risk or severity of adverse effects can be increased when Prasterone is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Prasterone.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Prasterone is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Prasterone.Approved, Vet Approved
DienestrolThe risk or severity of adverse effects can be increased when Prasterone is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe risk or severity of adverse effects can be increased when Prasterone is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Prasterone.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Prasterone.Approved
DihydroergotamineThe metabolism of Prasterone can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteronePrasterone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DiltiazemThe metabolism of Prasterone can be decreased when combined with Diltiazem.Approved
DistigmineThe risk or severity of adverse effects can be increased when Prasterone is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Prasterone is combined with Donepezil.Approved
DoxycyclineThe metabolism of Prasterone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Prasterone can be decreased when combined with Dronedarone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Prasterone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Prasterone.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Prasterone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Prasterone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Prasterone is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Prasterone is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Prasterone can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe risk or severity of adverse effects can be increased when Prasterone is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Prasterone.Approved
EquolThe risk or severity of adverse effects can be increased when Prasterone is combined with Equol.Investigational
ErythromycinThe metabolism of Prasterone can be decreased when combined with Erythromycin.Approved, Vet Approved
EstradiolThe risk or severity of adverse effects can be increased when Prasterone is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe risk or severity of adverse effects can be increased when Prasterone is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe risk or severity of adverse effects can be increased when Prasterone is combined with Estrogens, esterified.Approved
EstroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Estrone.Approved
Etacrynic acidPrasterone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Prasterone.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Prasterone.Experimental
Ethinyl EstradiolThe risk or severity of adverse effects can be increased when Prasterone is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Prasterone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Prasterone.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Prasterone.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Prasterone.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Prasterone.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Prasterone.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Prasterone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Prasterone.Approved
FenthionThe risk or severity of adverse effects can be increased when Prasterone is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Prasterone.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Prasterone.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Prasterone.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when Prasterone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Prasterone.Approved, Withdrawn
FluconazoleThe metabolism of Prasterone can be decreased when combined with Fluconazole.Approved
FlumequineThe risk or severity of adverse effects can be increased when Prasterone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Prasterone.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Prasterone.Experimental
FluoxymesteronePrasterone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Prasterone.Approved, Investigational
FluvoxamineThe metabolism of Prasterone can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Prasterone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Prasterone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Prasterone can be increased when combined with Fosphenytoin.Approved
FurosemidePrasterone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Prasterone can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Prasterone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Prasterone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Prasterone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Prasterone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Prasterone is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Prasterone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe risk or severity of adverse effects can be increased when Prasterone is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Prasterone is combined with GI-5005.Investigational
GLPG-0492Prasterone may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Prasterone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Prasterone is combined with Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Prasterone.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Prasterone.Experimental
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Prasterone is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Prasterone is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HexestrolThe risk or severity of adverse effects can be increased when Prasterone is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Prasterone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Prasterone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prasterone.Approved, Investigational
HydrochlorothiazidePrasterone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazidePrasterone may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Prasterone can be decreased when combined with Hydrotalcite.Experimental, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Prasterone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Prasterone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Prasterone.Approved
ImatinibThe metabolism of Prasterone can be decreased when combined with Imatinib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Prasterone.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Prasterone.Approved
IndapamidePrasterone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe metabolism of Prasterone can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Prasterone.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Prasterone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Prasterone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Prasterone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Prasterone is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Prasterone is combined with Ipidacrine.Experimental
IsavuconazoniumThe metabolism of Prasterone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Prasterone is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Prasterone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Prasterone.Withdrawn
IsradipineThe metabolism of Prasterone can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Prasterone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Prasterone can be increased when it is combined with Ivacaftor.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Prasterone.Experimental
KetoconazoleThe metabolism of Prasterone can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Prasterone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Prasterone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Prasterone.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Prasterone is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Prasterone.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Prasterone.Experimental
LopinavirThe metabolism of Prasterone can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Prasterone.Approved, Investigational
LovastatinThe metabolism of Prasterone can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Prasterone.Approved, Investigational
LuliconazoleThe serum concentration of Prasterone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Prasterone can be increased when combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Prasterone.Approved, Investigational
MagaldrateThe bioavailability of Prasterone can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe bioavailability of Prasterone can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Prasterone can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Prasterone can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Prasterone.Approved
Magnesium silicateThe bioavailability of Prasterone can be decreased when combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe bioavailability of Prasterone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Prasterone is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Prasterone.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prasterone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Prasterone.Approved
MefloquineThe risk or severity of adverse effects can be increased when Prasterone is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Prasterone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Prasterone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Prasterone.Approved
MesterolonePrasterone may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe risk or severity of adverse effects can be increased when Prasterone is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Prasterone.Investigational, Withdrawn
MethallenestrilThe risk or severity of adverse effects can be increased when Prasterone is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Prasterone is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazidePrasterone may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Prasterone.Approved, Vet Approved
MethyltestosteronePrasterone may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Prasterone is combined with Metoclopramide.Approved, Investigational
MetolazonePrasterone may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe serum concentration of Prasterone can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Prasterone is combined with Minaprine.Approved
MitotaneThe serum concentration of Prasterone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Prasterone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Prasterone.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Prasterone.Experimental
MoxestrolThe risk or severity of adverse effects can be increased when Prasterone is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Prasterone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prasterone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Prasterone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Prasterone.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Prasterone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Prasterone is combined with Nalidixic Acid.Approved, Investigational
NandrolonePrasterone may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
Nandrolone decanoatePrasterone may increase the fluid retaining activities of Nandrolone decanoate.Approved, Illicit
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Prasterone.Approved, Vet Approved
NefazodoneThe metabolism of Prasterone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Prasterone can be decreased when combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Prasterone is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Prasterone is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Prasterone.Approved
NetupitantThe serum concentration of Prasterone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Prasterone can be increased when combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Prasterone is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Prasterone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Prasterone.Approved
NilotinibThe metabolism of Prasterone can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Prasterone.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Prasterone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Prasterone is combined with Norfloxacin.Approved
OlaparibThe metabolism of Prasterone can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Prasterone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Prasterone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Prasterone.Vet Approved
OsimertinibThe serum concentration of Prasterone can be increased when it is combined with Osimertinib.Approved
OxandrolonePrasterone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Prasterone.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Prasterone is combined with Oxolinic acid.Experimental
OxymetholonePrasterone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Prasterone.Approved, Withdrawn
PalbociclibThe serum concentration of Prasterone can be increased when it is combined with Palbociclib.Approved
ParaoxonThe risk or severity of adverse effects can be increased when Prasterone is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Prasterone.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Prasterone.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Prasterone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Prasterone is combined with Pefloxacin.Approved
PentobarbitalThe metabolism of Prasterone can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Prasterone can be increased when combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Prasterone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Prasterone.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Prasterone.Approved, Investigational
PhenytoinThe metabolism of Prasterone can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Prasterone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Prasterone.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Prasterone is combined with Pipemidic acid.Experimental
PiretanidePrasterone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Prasterone.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Prasterone is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Prasterone.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Prasterone.Experimental
Polyestradiol phosphateThe risk or severity of adverse effects can be increased when Prasterone is combined with Polyestradiol phosphate.Approved
PolythiazidePrasterone may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe metabolism of Prasterone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Prasterone.Experimental, Investigational
PrimidoneThe metabolism of Prasterone can be increased when combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Prasterone.Experimental
PromestrieneThe risk or severity of adverse effects can be increased when Prasterone is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Prasterone.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Prasterone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Prasterone.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Prasterone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Prasterone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Prasterone is combined with Pyridostigmine.Approved
QuinestrolThe risk or severity of adverse effects can be increased when Prasterone is combined with Quinestrol.Approved
QuinethazonePrasterone may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Prasterone is combined with Rabies virus inactivated antigen, A.Approved
RanolazineThe metabolism of Prasterone can be decreased when combined with Ranolazine.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Prasterone.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Prasterone.Approved, Experimental, Investigational
RifabutinThe metabolism of Prasterone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Prasterone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Prasterone can be increased when combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Prasterone is combined with Rindopepimut.Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Prasterone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Prasterone.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Prasterone is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Prasterone is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Prasterone is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Prasterone is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Prasterone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Prasterone.Approved, Vet Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Prasterone is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Prasterone.Approved
SaquinavirThe metabolism of Prasterone can be decreased when combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe risk or severity of adverse effects can be increased when Prasterone is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Prasterone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Prasterone.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Prasterone.Investigational
SildenafilThe metabolism of Prasterone can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Prasterone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Prasterone can be increased when it is combined with Simeprevir.Approved
SitafloxacinThe risk or severity of adverse effects can be increased when Prasterone is combined with Sitafloxacin.Experimental, Investigational
Sodium bicarbonateThe bioavailability of Prasterone can be decreased when combined with Sodium bicarbonate.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Prasterone is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Prasterone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Prasterone.Investigational
St. John's WortThe serum concentration of Prasterone can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StanozololPrasterone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Prasterone can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Prasterone.Approved
SulfisoxazoleThe metabolism of Prasterone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Prasterone.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Prasterone.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Prasterone.Experimental
Synthetic Conjugated Estrogens, AThe risk or severity of adverse effects can be increased when Prasterone is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe risk or severity of adverse effects can be increased when Prasterone is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Prasterone is combined with Tacrine.Investigational, Withdrawn
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Prasterone.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Prasterone is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Prasterone.Approved, Withdrawn
TelithromycinThe metabolism of Prasterone can be decreased when combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Prasterone is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Prasterone.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Prasterone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Prasterone.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Prasterone.Approved
TestosteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Testosterone.Approved, Investigational
Testosterone PropionatePrasterone may increase the fluid retaining activities of Testosterone Propionate.Approved, Vet Approved
TG4010The risk or severity of adverse effects can be increased when Prasterone is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Prasterone.Approved
TiboloneThe risk or severity of adverse effects can be increased when Prasterone is combined with Tibolone.Approved, Investigational
TiclopidineThe metabolism of Prasterone can be decreased when combined with Ticlopidine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Prasterone.Investigational
TocilizumabThe serum concentration of Prasterone can be decreased when it is combined with Tocilizumab.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Prasterone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Prasterone.Approved
TorasemidePrasterone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Prasterone.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Prasterone.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Prasterone is combined with Trichlorfon.Vet Approved
TrichlormethiazidePrasterone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Prasterone.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Prasterone.Approved
TromethamineThe bioavailability of Prasterone can be decreased when combined with Tromethamine.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Prasterone is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Prasterone is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Prasterone.Investigational, Withdrawn
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Prasterone is combined with Zoster vaccine.Approved
VenlafaxineThe metabolism of Prasterone can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Prasterone can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Prasterone can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinPrasterone may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when Prasterone is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Prasterone.Approved, Investigational
ZeranolThe risk or severity of adverse effects can be increased when Prasterone is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Prasterone.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Prasterone can be decreased when combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Prasterone.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Isao Sugimoto, Yoko Sawase, "Stable preparation of water-soluble salts of dehydroepiandrosterone sulfate for parenteral administration." U.S. Patent US4061744, issued January, 1977.

US4061744
General References
  1. Baker WL, Karan S, Kenny AM: Effect of dehydroepiandrosterone on muscle strength and physical function in older adults: a systematic review. J Am Geriatr Soc. 2011 Jun;59(6):997-1002. doi: 10.1111/j.1532-5415.2011.03410.x. Epub 2011 Jun 7. [PubMed:21649617]
  2. Alkatib AA, Cosma M, Elamin MB, Erickson D, Swiglo BA, Erwin PJ, Montori VM: A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab. 2009 Oct;94(10):3676-81. doi: 10.1210/jc.2009-0672. Epub 2009 Sep 22. [PubMed:19773400]
  3. Arlt W: Dehydroepiandrosterone and ageing. Best Pract Res Clin Endocrinol Metab. 2004 Sep;18(3):363-80. [PubMed:15261843]
  4. Wallace MB, Lim J, Cutler A, Bucci L: Effects of dehydroepiandrosterone vs androstenedione supplementation in men. Med Sci Sports Exerc. 1999 Dec;31(12):1788-92. [PubMed:10613429]
  5. Grimley Evans J, Malouf R, Huppert F, van Niekerk JK: Dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly people. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006221. [PubMed:17054283]
  6. Fuller SJ, Tan RS, Martins RN: Androgens in the etiology of Alzheimer's disease in aging men and possible therapeutic interventions. J Alzheimers Dis. 2007 Sep;12(2):129-42. [PubMed:17917157]
  7. Thijs L, Fagard R, Forette F, Nawrot T, Staessen JA: Are low dehydroepiandrosterone sulphate levels predictive for cardiovascular diseases? A review of prospective and retrospective studies. Acta Cardiol. 2003 Oct;58(5):403-10. [PubMed:14609305]
  8. Barrett-Connor E, Khaw KT, Yen SS: A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med. 1986 Dec 11;315(24):1519-24. [PubMed:2946952]
  9. Arnlov J, Pencina MJ, Amin S, Nam BH, Benjamin EJ, Murabito JM, Wang TJ, Knapp PE, D'Agostino RB Sr, Bhasin S, Vasan RS: Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med. 2006 Aug 1;145(3):176-84. [PubMed:16880459]
  10. Crosbie D, Black C, McIntyre L, Royle PL, Thomas S: Dehydroepiandrosterone for systemic lupus erythematosus. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD005114. [PubMed:17943841]
  11. Mattison JA, Lane MA, Roth GS, Ingram DK: Calorie restriction in rhesus monkeys. Exp Gerontol. 2003 Jan-Feb;38(1-2):35-46. [PubMed:12543259]
  12. Roberts E: The importance of being dehydroepiandrosterone sulfate (in the blood of primates): a longer and healthier life? Biochem Pharmacol. 1999 Feb 15;57(4):329-46. [PubMed:9933021]
  13. Leblanc M, Labrie C, Belanger A, Candas B, Labrie F: Bioavailability and pharmacokinetics of dehydroepiandrosterone in the cynomolgus monkey. J Clin Endocrinol Metab. 2003 Sep;88(9):4293-302. [PubMed:12970301]
  14. Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE: Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Hum Reprod. 2000 Oct;15(10):2129-32. [PubMed:11006185]
  15. Chang DM, Lan JL, Lin HY, Luo SF: Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Nov;46(11):2924-7. [PubMed:12428233]
  16. The NIH National Library of Medicine [Link]
External Links
KEGG Drug
D08409
KEGG Compound
C01227
PubChem Compound
5881
PubChem Substance
46508824
ChemSpider
5670
BindingDB
50223368
ChEBI
28689
ChEMBL
CHEMBL90593
Therapeutic Targets Database
DNC001146
PharmGKB
PA451993
IUPHAR
2370
Guide to Pharmacology
GtP Drug Page
HET
AND
Wikipedia
Dehydroepiandrosterone
ATC Codes
A14AA07 — PrasteroneG03EA03 — Prasterone and estrogen
PDB Entries
1coy / 1e3r / 1j99 / 1q22 / 3dhe
MSDS
Download (19.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingSupportive CareCognitive Dysfunctions1
0Not Yet RecruitingOtherDiabetes, Diabetes Mellitus Type 11
0RecruitingOtherDiabetes, Diabetes Mellitus Type 11
0WithdrawnTreatmentPremature Ovarian Failure (POF)1
1CompletedNot AvailableParkinson's Disease (PD)1
1CompletedTreatmentIrregular Menses1
1CompletedTreatmentVulvovaginal Atrophy1
1RecruitingSupportive CareHealthy Women / Women With Ovarian Reserve Diminish1
1TerminatedTreatmentCancer, Breast2
1, 2RecruitingTreatmentSynovial Sarcoma1
2CompletedPreventionMultiple Myeloma and Plasma Cell Neoplasm1
2CompletedTreatmentCrohn's Disease (CD)1
2CompletedTreatmentDepressive Disorders / Moods Disorders1
2CompletedTreatmentErectile Dysfunction (ED)1
2CompletedTreatmentGingival Inflammation / Inflammatory Reaction / Periodontitis1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentLacrimal Apparatus Diseases / Salivary Gland Diseases / Sjögren's Syndrome / Xerostomia1
2CompletedTreatmentLibido1
2CompletedTreatmentLupus Erythematosus, Systemic / Sjögren's Syndrome1
2CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
2TerminatedTreatmentAndrogen Receptor Gene Overexpression / Estrogen Receptor Negative Neoplasm / Estrogen Receptor Positive Breast Cancer / Metastatic Breastcancer / Progesterone Receptor Negative Neoplasm / Progesterone Receptor Positive Tumor1
2Unknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD) / Pulmonary Hypertension (PH)1
2, 3CompletedTreatmentAbstinence Syndrome / Behavior, Addictive1
2, 3CompletedTreatmentAnorexia Nervosa (AN)1
2, 3CompletedTreatmentMenopausal Hot Flushes1
2, 3CompletedTreatmentSystemic Lupus Erythematosus (SLE)2
2, 3Unknown StatusTreatmentChanges in AMH / Diminished Ovarian Reserve (DOR) / Efficacy of DHEA / Pregnancy Rate1
3Active Not RecruitingSupportive CareCancer, Breast / Gynecologic Cancers1
3CompletedTreatmentAddison's Disease1
3CompletedTreatmentAdrenal Insufficiency1
3CompletedTreatmentAnorexia Nervosa (AN)1
3CompletedTreatmentArtificial Reproduction Technology / Dehydroepiandrosterone / DHEAS / Gene Expression of Cumulus Cells / Ovarian Hyper-stimulation Protocol1
3CompletedTreatmentDiminished Ovarian Reserve (DOR) / Infertilities / Ovarian Aging / Predicted Poor-responders1
3CompletedTreatmentHealthy Volunteers1
3CompletedTreatmentLibido Disorder / Menopausal Syndromes / Quality of Life1
3CompletedTreatmentMenopausal Hot Flushes / Vasomotor Symptoms1
3CompletedTreatmentPregnancy2
3CompletedTreatmentQuality of Life / Skin Aging1
3CompletedTreatmentSubfertility1
3CompletedTreatmentSystemic Lupus Erythematosus (SLE)2
3CompletedTreatmentVulvovaginal Atrophy5
3RecruitingPreventionPremature Births1
3RecruitingTreatmentHypoactive Sexual Desire Disorder (HSDD)1
3RecruitingTreatmentSubfertility2
3Unknown StatusPreventionLupus1
3Unknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD) / Pulmonary Hypertension (PH)1
4Active Not RecruitingTreatmentInfertilities1
4CompletedPreventionMacular Pigment Optical Density1
4CompletedTreatmentInfertilities1
4RecruitingTreatmentSubfertility1
4Unknown StatusTreatmentSjögren's Syndrome1
Not AvailableActive Not RecruitingPreventionType 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableInfertilities1
Not AvailableCompletedPreventionAging / BMI >30 kg/m2 / Insulin Resistance1
Not AvailableCompletedPreventionHealthy Volunteers1
Not AvailableCompletedTreatmentAdrenal Insufficiency1
Not AvailableCompletedTreatmentAging1
Not AvailableCompletedTreatmentCancer Cachexia1
Not AvailableRecruitingTreatmentSubfertility1
Not AvailableUnknown StatusTreatmentHypoactive Sexual Desire Disorder (HSDD)1
Not AvailableWithdrawnTreatmentInfertilities1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
InsertVaginal6.5 mg/1
KitOral
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8268806No2011-03-192031-03-19Us
US8629129No2008-08-072028-08-07Us
US8957054No2008-08-072028-08-07Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)140-141 °CPhysProp
water solubility63.5 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.23HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0438 mg/mLALOGPS
logP3.53ALOGPS
logP3.36ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)18.2ChemAxon
pKa (Strongest Basic)-1.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity84.66 m3·mol-1ChemAxon
Polarizability34.09 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9611
Caco-2 permeable+0.8816
P-glycoprotein substrateSubstrate0.6176
P-glycoprotein inhibitor IInhibitor0.6272
P-glycoprotein inhibitor IINon-inhibitor0.9014
Renal organic cation transporterNon-inhibitor0.7596
CYP450 2C9 substrateNon-substrate0.8415
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7404
CYP450 1A2 substrateNon-inhibitor0.9313
CYP450 2C9 inhibitorNon-inhibitor0.9672
CYP450 2D6 inhibitorNon-inhibitor0.9476
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8399
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9013
Ames testNon AMES toxic0.9382
CarcinogenicityNon-carcinogens0.947
BiodegradationNot ready biodegradable0.8998
Rat acute toxicity1.5214 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8861
hERG inhibition (predictor II)Non-inhibitor0.7176
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MS (1 MEOX; 1 TMS)GC-MSsplash10-004i-4920000000-9dc14963a290268534b8
GC-MS Spectrum - GC-MS (1 TMS)GC-MSsplash10-004i-3910000000-2bbc760dbeb7f9f1ebfc
GC-MS Spectrum - EI-BGC-MSsplash10-0abi-1790000000-52f5e67bc4d1fab73561
Mass Spectrum (Electron Ionization)MSsplash10-0a4l-6940000000-948ad487c238d48aa9be
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0fk9-0190000000-66ac82624767dc6821e5
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0w90-1690000000-b3a231fc509b7a34e09c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-08gj-1930000000-309dc082cc36ec9dcd8c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-06sj-2910000000-378638f2a861c948f79d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0536-3900000000-72e80e1a07c4d3a40a7a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0036-4900000000-26c8272483a80d1b5eab
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-0290000000-1a3588ca5d5bacb9ad30
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0bta-3920000000-2df257db43df6cc86570
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Androstane steroids
Direct Parent
Androgens and derivatives
Alternative Parents
3-beta-hydroxysteroids / 3-beta-hydroxy delta-5-steroids / 17-oxosteroids / Delta-5-steroids / Secondary alcohols / Ketones / Cyclic alcohols and derivatives / Organic oxides / Hydrocarbon derivatives
Substituents
Androgen-skeleton / 3-hydroxy-delta-5-steroid / 3-hydroxysteroid / 3-beta-hydroxysteroid / 3-beta-hydroxy-delta-5-steroid / Oxosteroid / 17-oxosteroid / Hydroxysteroid / Delta-5-steroid / Cyclic alcohol
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
3beta-hydroxy steroid, 17-oxo steroid, androstanoid (CHEBI:28689) / C19 steroids (androgens) and derivatives, Androstane and derivatives, Androgens (C01227) / C19 steroids (androgens) and derivatives (LMST02020021)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissu...
Gene Name
ESR1
Uniprot ID
P03372
Uniprot Name
Estrogen receptor
Molecular Weight
66215.45 Da
References
  1. Chen F, Knecht K, Birzin E, Fisher J, Wilkinson H, Mojena M, Moreno CT, Schmidt A, Harada S, Freedman LP, Reszka AA: Direct agonist/antagonist functions of dehydroepiandrosterone. Endocrinology. 2005 Nov;146(11):4568-76. Epub 2005 Jun 30. [PubMed:15994348]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Activator
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent m...
Gene Name
ESR2
Uniprot ID
Q92731
Uniprot Name
Estrogen receptor beta
Molecular Weight
59215.765 Da
References
  1. Chen F, Knecht K, Birzin E, Fisher J, Wilkinson H, Mojena M, Moreno CT, Schmidt A, Harada S, Freedman LP, Reszka AA: Direct agonist/antagonist functions of dehydroepiandrosterone. Endocrinology. 2005 Nov;146(11):4568-76. Epub 2005 Jun 30. [PubMed:15994348]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...

Components:
References
  1. Sousa A, Ticku MK: Interactions of the neurosteroid dehydroepiandrosterone sulfate with the GABA(A) receptor complex reveals that it may act via the picrotoxin site. J Pharmacol Exp Ther. 1997 Aug;282(2):827-33. [PubMed:9262347]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Voltage-gated cation channel activity
Specific Function
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic p...

Components:
References
  1. Compagnone NA, Mellon SH: Dehydroepiandrosterone: a potential signalling molecule for neocortical organization during development. Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4678-83. [PubMed:9539798]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription ...
Gene Name
AR
Uniprot ID
P10275
Uniprot Name
Androgen receptor
Molecular Weight
98987.9 Da
References
  1. Chen F, Knecht K, Birzin E, Fisher J, Wilkinson H, Mojena M, Moreno CT, Schmidt A, Harada S, Freedman LP, Reszka AA: Direct agonist/antagonist functions of dehydroepiandrosterone. Endocrinology. 2005 Nov;146(11):4568-76. Epub 2005 Jun 30. [PubMed:15994348]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Testosterone dehydrogenase (nad+) activity
Specific Function
Favors the reduction of estrogens and androgens. Also has 20-alpha-HSD activity. Uses preferentially NADH.
Gene Name
HSD17B1
Uniprot ID
P14061
Uniprot Name
Estradiol 17-beta-dehydrogenase 1
Molecular Weight
34949.715 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sulfotransferase activity
Specific Function
Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfonation of steroids and bile acids in the liver and adrenal glands.
Gene Name
SULT2A1
Uniprot ID
Q06520
Uniprot Name
Bile salt sulfotransferase
Molecular Weight
33779.57 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Steroid sulfotransferase activity
Specific Function
Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfate conjugation of many hormones, neurotransmitters, drugs and xenobiotic compounds. Sulf...
Gene Name
SULT2B1
Uniprot ID
O00204
Uniprot Name
Sulfotransferase family cytosolic 2B member 1
Molecular Weight
41307.32 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Activator
General Function
Zinc ion binding
Specific Function
Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleyleth...
Gene Name
PPARA
Uniprot ID
Q07869
Uniprot Name
Peroxisome proliferator-activated receptor alpha
Molecular Weight
52224.595 Da
References
  1. Kohalmy K, Tamasi V, Kobori L, Sarvary E, Pascussi JM, Porrogi P, Rozman D, Prough RA, Meyer UA, Monostory K: Dehydroepiandrosterone induces human CYP2B6 through the constitutive androstane receptor. Drug Metab Dispos. 2007 Sep;35(9):1495-501. Epub 2007 Jun 25. [PubMed:17591676]
  2. Tamasi V, Miller KK, Ripp SL, Vila E, Geoghagen TE, Prough RA: Modulation of receptor phosphorylation contributes to activation of peroxisome proliferator activated receptor alpha by dehydroepiandrosterone and other peroxisome proliferators. Mol Pharmacol. 2008 Mar;73(3):968-76. Epub 2007 Dec 13. [PubMed:18079279]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
Functions in lipid transport from the endoplasmic reticulum and is involved in a wide array of cellular functions probably through regulation of the biogenesis of lipid microdomains at the plasma m...
Gene Name
SIGMAR1
Uniprot ID
Q99720
Uniprot Name
Sigma non-opioid intracellular receptor 1
Molecular Weight
25127.52 Da
References
  1. Waterhouse RN, Chang RC, Atuehene N, Collier TL: In vitro and in vivo binding of neuroactive steroids to the sigma-1 receptor as measured with the positron emission tomography radioligand [18F]FPS. Synapse. 2007 Jul;61(7):540-6. [PubMed:17447254]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Activator
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism an...
Gene Name
NR1I2
Uniprot ID
O75469
Uniprot Name
Nuclear receptor subfamily 1 group I member 2
Molecular Weight
49761.245 Da
References
  1. Kohalmy K, Tamasi V, Kobori L, Sarvary E, Pascussi JM, Porrogi P, Rozman D, Prough RA, Meyer UA, Monostory K: Dehydroepiandrosterone induces human CYP2B6 through the constitutive androstane receptor. Drug Metab Dispos. 2007 Sep;35(9):1495-501. Epub 2007 Jun 25. [PubMed:17591676]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Activator
General Function
Zinc ion binding
Specific Function
Binds and transactivates the retinoic acid response elements that control expression of the retinoic acid receptor beta 2 and alcohol dehydrogenase 3 genes. Transactivates both the phenobarbital re...
Gene Name
NR1I3
Uniprot ID
Q14994
Uniprot Name
Nuclear receptor subfamily 1 group I member 3
Molecular Weight
39942.145 Da
References
  1. Kohalmy K, Tamasi V, Kobori L, Sarvary E, Pascussi JM, Porrogi P, Rozman D, Prough RA, Meyer UA, Monostory K: Dehydroepiandrosterone induces human CYP2B6 through the constitutive androstane receptor. Drug Metab Dispos. 2007 Sep;35(9):1495-501. Epub 2007 Jun 25. [PubMed:17591676]
Kind
Protein
Organism
Pseudomonas putida
Pharmacological action
Unknown
General Function
Steroid delta-isomerase activity
Specific Function
Not Available
Gene Name
ksi
Uniprot ID
P07445
Uniprot Name
Steroid Delta-isomerase
Molecular Weight
14535.48 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Brevibacterium sterolicum
Pharmacological action
Unknown
General Function
Steroid delta-isomerase activity
Specific Function
Catalyzes the oxidation and isomerization of cholesterol to cholestenone (4-cholesten-3-one), which is an initial step in the cholesterol degradation process.
Gene Name
choB
Uniprot ID
P22637
Uniprot Name
Cholesterol oxidase
Molecular Weight
59357.765 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on December 01, 2017 14:47